Impact of Disorders of Gonadal Function in Childhood and Adolescence on Growth Patterns and Outcomes



Height achieved by the end of adolescence depends on normal nutrition, adequate growth factors, intact gonadal function with normal progress through puberty, together with maintenance of adult sex hormone levels and bones that are capable of response. Adequate gonadal function is the most important determinant of outcome of linear growth and bone health by the end of adolescence. As outcomes of chronic and life-threatening childhood illness improve, the focus increasingly shifts to maximizing long-term health outcomes. Many disorders adversely impact upon gonadal function, including both primary gonadal abnormalities and problems secondary to chronic illness or to treatments such as radiation, chemotherapy or long-term transfusion needs. Timing of onset of a disease process, degree of systemic ill health and specific adverse effects on bone growth all alter overall impact on the individual. Growth patterns may change as gonadal dysfunction evolves. Understanding the variations in linear growth pattern due to disorders and their treatments alerts the paediatrician to a need for timely intervention. Disorders of pubertal onset, precocious or delayed, may be accompanied by significant psychosocial and emotional disturbance. Physician awareness of need for psychological support is essential. Ethical issues concerning choices for treatment modality made by parents on behalf of their children require consideration. A detailed understanding of the pivotal issue of promoting gonadal health and maintaining function for the future is essential for good-quality long-term health outcomes.


Linear Growth Growth Hormone Deficiency Congenital Adrenal Hyperplasia Turner Syndrome Final Height 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Adrenocorticotrophic hormone


Anti-Mullerian hormone


Congenital adrenal hyperplasia


Follicle-stimulating hormone


Growth hormone


Gonadotropin-releasing hormone


G protein receptor


Guanosine triphosphatase


Human chorionic gonadotrophin


Hypothalamic hypogonadism


Hypothalamic–pituitary axis


Hormone replacement treatment


Immunoglobulin A


Insulin-like growth factor 1


Luteinizing hormone


Osteogenesis imperfecta


Steroidogenic factor 1


Thyroid-stimulating hormone



The growth charts have been adapted, with permission, from standard growth charts produced by Pfizer.


  1. Armstrong GT, Chow EJ, Sklar CA. Alterations in pubertal timing following therapy for childhood malignancies. Endocr Dev. 2009a;15:25–39.PubMedCrossRefGoogle Scholar
  2. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009b;101:946–58. EpubJun 17.PubMedCrossRefGoogle Scholar
  3. Berry GT. Galactosemia and amenorrhea in the adolescent. Ann N Y Acad Sci. 2008;1135:112–7.PubMedCrossRefGoogle Scholar
  4. Birgit B, Julius H, Carsten R, Maryam S, Gabriel F, Victoria K, Margareta F, Outi H. Fertility preservation in girls with Turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin Endocrinol Metab. 2009;94:74–80.PubMedCrossRefGoogle Scholar
  5. Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, Jones C, Quigley CA, Binder G. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res. 2009;71:167–72.PubMedCrossRefGoogle Scholar
  6. Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, Braun L, Rappold G. SHOX Study Group Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92:219–28.PubMedCrossRefGoogle Scholar
  7. Bondy CA. Heart disease in Turner syndrome. Minerva Endocrinol. 2007;32:245–61.PubMedGoogle Scholar
  8. Bondy CA. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril. 2008;90 Suppl:S185–6.Google Scholar
  9. Bonjour JP, Chevalley T, Ferrari S, Rizzoli R. The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publ Mex. 2009;51 Suppl 1:S5–17.Google Scholar
  10. Brown J, Zacharin M. Proposals for prevention and management of steroid induced osteoporosis in children and adolescents. J Paediatr Child Health. 2005;41:553–57.PubMedCrossRefGoogle Scholar
  11. Colvin SC, Mullen RD, Pfaeffle RW, Rhodes SJ. LHX3 and LHX4 transcription factors in pituitary development and disease. Pediatr Endocrinol Rev. 2009;6 Suppl 2:283–90.PubMedGoogle Scholar
  12. Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant. 2001;28:67–75.PubMedCrossRefGoogle Scholar
  13. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy revisited. Endocr Dev. 2009;15:1–24.PubMedCrossRefGoogle Scholar
  14. Darzy KH, Thorner MO, Shalet SM. Cranially irradiated adult cancer survivors may have normal spontaneous GH secretion in the presence of discordant peak GH responses to stimulation tests (compensated GH deficiency). Clin Endocrinol (Oxf). 2009;70:287–93.CrossRefGoogle Scholar
  15. Ehtisham S, Zacharin M. Primary ovarian failure and small for gestational age – a previously unrecognized association J Paediatr Child Health. 2009;45:313–6.PubMedCrossRefGoogle Scholar
  16. Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update. 2006;12:573–84.PubMedCrossRefGoogle Scholar
  17. Fricke O, Schoenau E. ‘The functional muscle bone unit’: probing the relevance of mechanical signals for bone development in children and adolescents. Growth Horm IGF Res. 2007;17:1–9.PubMedCrossRefGoogle Scholar
  18. George AM, Jones PM, Middleton PG. Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiol Lett. 2009;300:153–64.PubMedCrossRefGoogle Scholar
  19. Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocr Relat Cancer. 2004;11:589–602.PubMedCrossRefGoogle Scholar
  20. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–52.PubMedCrossRefGoogle Scholar
  21. Green DM, Sklar CA, Boice JD, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2374–81.PubMedCrossRefGoogle Scholar
  22. Henry YM, Fatayerji D, Eastell R. Attainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric density. Osteoporos Int. 2004;15:263–73.PubMedCrossRefGoogle Scholar
  23. Herbison AE. Genetics of puberty. Horm Res. 2007;68 Suppl 5:75–9.PubMedCrossRefGoogle Scholar
  24. Jayasinghe Y, Sawyer S, Zacharin M. Current concepts in bone and reproductive health in adolescents with anorexia nervosa. Am J Obstet Gynecol. 2008;115:304–15.Google Scholar
  25. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab. 2007;92:2030–2.CrossRefGoogle Scholar
  26. Lala R, Andreo M, Pucci A, Matarazzo P. Persistent hyperestrogenism after precocious puberty in young females with McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007;Suppl 4:423–8.Google Scholar
  27. Littley MD, Shalet SM, Beardwell CG, Robinson EL, Sutton ML. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf). 1989;31:363–73.CrossRefGoogle Scholar
  28. Liu P, Gebski V, Turner L, Conway A, Wishart S, Handelsman D. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin deficient infertile men. Hum Reprod. 2002;17:625–33.PubMedCrossRefGoogle Scholar
  29. Lourenco D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, Boudjenah R, Guerrs Junior G, Maciel-Guerra AT, Achermann McElreavey K, Bashamboo AJC. Mutations in NR5A1associated with ovarian insufficiency. N Engl J Med. 2009;360:1200–10.PubMedCrossRefGoogle Scholar
  30. Lu P, Briody J, Ogle G, Morley K, Humphries I, Allen J, Howman Giles R, Sillence D, Cowell C. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res. 1994;9:1451–8.PubMedCrossRefGoogle Scholar
  31. Lu PW, Cowell CT, Lloyd Jones SA Briody JN, Howman-Giles R. Volumetric bone mineral density in normal subjects aged 5–27 years. J Clin Endocrinol Metab. 1996;81:1586–90.PubMedCrossRefGoogle Scholar
  32. Merchant TE, Williams T, Smith JM, Rose SR, Danish RK, Burghen GA, Kunnn LE, Lustig RH. Pre irradiation endocrinopathies in paediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys. 2002;54:45–50.PubMedCrossRefGoogle Scholar
  33. Mieszczak J, Lowe ES, Plourder P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab. 2008;93:2751–4.PubMedCrossRefGoogle Scholar
  34. Mullis PE. Genetics of growth hormone deficiency. Endocrinol Metab Clin North Am. 2007;36:17–36.PubMedCrossRefGoogle Scholar
  35. Nandagopal R, Laverdière C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res. 2008;69:65–74.PubMedCrossRefGoogle Scholar
  36. Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab. 1994;78:1282–6.PubMedCrossRefGoogle Scholar
  37. Poomthavorn P, Stargatt R, Zacharin M. Psychosexual and psychosocial functions of anorchid young adults. J Clin Endocrinol Metab. 2009;94:2502–5.PubMedCrossRefGoogle Scholar
  38. Pringle PJ, Stanhope R, Hindmarsh P, Brook CG. Abnormal pubertal development in primary hypothyroidism. Clin Endocrinol (Oxf). 1988;28:479–86.CrossRefGoogle Scholar
  39. Pyett P, Rayner J, Venn A, Bruinsma F, Werther G, Lumley J. Using hormone treatment to reduce the adult height of tall girls: are women satisfied with the decision in later years? Soc Sci Med. 2005;61:1629–39.PubMedCrossRefGoogle Scholar
  40. Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol. 2007;156:105–11.PubMedCrossRefGoogle Scholar
  41. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18:610–4.PubMedCrossRefGoogle Scholar
  42. Rivkees S, Crawford J. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Paediatrics. 2000;106:767–73.CrossRefGoogle Scholar
  43. Rose SR, Schreiber RE, Kearney NS, Lustig RH, Danish RK, Burghen GA, Hudson MM. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab. 2004;17:55–66.PubMedGoogle Scholar
  44. Rosenfield R, Devine N, Hunold J, Mauras N, Moshang T, Root A. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab. 2005;90:6424–3.PubMedCrossRefGoogle Scholar
  45. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhemsen K, Lin A, Lippe B, Pasquino AM, Ranke MB, Rosenfeld R, Silberbach M. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab. 2001;86:3061–9.PubMedCrossRefGoogle Scholar
  46. Saggese G, Baroncelli GI, Bertelloni S. Puberty and bone development. Best Pract Res Clin Endocrinol Metab. 2002;1:53–64.CrossRefGoogle Scholar
  47. Sanders RD, Spencer JB, Epstein MP, Pollak SV, Vardhana PA, Lustbader JW, Fridovich-Keil JL. Biomarkers of ovarian function in girls and women with classic galactosemia. Fertil Steril. 2009;92:344–51.PubMedCrossRefGoogle Scholar
  48. Seeman E. Sexual dimorphism in skeletal size, density and strength. J Clin Endocrinol Metab. 2001;86:4576–84.PubMedCrossRefGoogle Scholar
  49. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25:786–91.PubMedCrossRefGoogle Scholar
  50. Shalet SM. Endocrine sequelae of cancer therapy. Eur J Endocrinol. 1996;135:135–43.PubMedCrossRefGoogle Scholar
  51. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005;25–7.Google Scholar
  52. Stewart C, Lynch A. Undue influence, consent and medical treatment. J R Soc Med. 2003;96:598–601.PubMedCrossRefGoogle Scholar
  53. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998;22:989–94.PubMedCrossRefGoogle Scholar
  54. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688–95.PubMedCrossRefGoogle Scholar
  55. Wierman ME, Beardsworth DE, Mansfield MJ, Badger TM, Crawford JD, CriglerJF Jr, Bode HH, Loughlin JS, Kushner DC, Scully RE, et al. Puberty without gonadotropins. A unique mechanism of sexual development.N Engl J Med. 1985;312:65–72.PubMedCrossRefGoogle Scholar
  56. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Neurol India. 2008;56:236–47.PubMedCrossRefGoogle Scholar
  57. Zacharin M. Use of androgens and oestrogens in adolescents – a review of hormone replacement treatment. J Pediatr Endocrinol Metab. 2000;13:3–11.PubMedCrossRefGoogle Scholar
  58. Zacharin M. Assessing the skeleton in children and adolescents with disabilities: avoiding pitfalls, maximizing outcomes. A guide for the general paediatrician. J Paediatr Child Health. 2009a; May 28 epub.Google Scholar
  59. Zacharin M. Disorders of ovarian function in childhood and adolescence : evolving needs of the growing child. An endocrine perspective. Br J Obstet Gynaecol. 2010;117(2):156–62.Google Scholar
  60. Zacharin M. Puberty, contraception, and hormonal management for young people with disabilities. Clin Pediatr (Phila). 2009c;48:149–55.CrossRefGoogle Scholar
  61. Zacharin M. Fertility induction with HCG and FSH in males with hypogonadotrophic hypogonadism is more rapid and more effective when used in adolescence abstract Lawson Wilkins Society/ESPE annu meeting; 2009d.Google Scholar
  62. Zacharin M, Kanamakala S. Pamidronate treatment of less severe types of Osteogenesis Imperfecta in children.J Paediatr Endocrinol Metab. 2004;17:1511–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Endocrinology and DiabetesThe Royal Children’s HospitalParkvilleAustralia

Personalised recommendations